Chronic ACT-335827 treatment in combination with CAF diet feeding showed a trend to impair glucose tolerance but did not significantly alter the levels or time course of blood glucose elevations upon challenge [ Treatment : F (1, 17) = 4.28, p = 0.054; Treatment × Time : F (4, 68) = 0.23, p = 0.92; Figure 5B ], or the AUC glucose [ t (17) = 1.80, p = 0.09].
← all excerpts
The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome.
1
—
—